Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zipalertinib in Advanced NSCLC With EGFR Mutations
NCT05967689Phase 2Recruiting
- Sponsor
- Taiho Oncology
- Start
- Jul 2023
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, randomised, open-label trial of zipalertinib in non-small cell lung cancer (NSCLC) (8 arms), sponsored by Taiho Oncology. Primary endpoint: Objective Response Rate. Started Jul 2023; status: recruiting.
02
Drugs
zipalertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05967689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05967689.